Optibrium expands UK head office with new facilities on Cambridge Innovation Park

PRESS RELEASE

08 June 2022

Optibrium expands UK head office with new facilities on Cambridge Innovation Park

• Investment in new headquarters forms part of ongoing company growth plans
• The new facility supports the continued success of Optibrium's drug discovery technologies and accommodates an expanding team

CAMBRIDGE, UK, 08 June 2022: Optibrium™, a developer of software for drug discovery, today announced the expansion of its UK headquarters with a move to larger office premises on Cambridge Innovation Park North. The new facilities accommodate Optibrium's accelerated growth and ongoing recruitment efforts to support the continued success and development of the company's innovative technology focused on improving the efficiency and productivity of the drug discovery process.

Optibrium's new headquarters, located in one of the UK's leading technology hubs, provide new offices, meeting rooms, social areas and on-site leisure activities to promote employee well-being. The premises will facilitate recruitment opportunities created by the company's ongoing expansion and commercial development, such as for C++ Software Engineers, DevOps Engineers and Researchers.

Over 170 organisations worldwide, including leading pharmaceutical companies, deploy Optibrium's computational drug discovery technology in their research programs. Its lead product, StarDrop™, is a comprehensive suite of integrated software for small molecule design, optimisation, and data analysis that enhances the speed and productivity of the drug discovery process. Cerella™, Optibrium's proven artificial intelligence platform, empowers project teams with valuable insights from complex drug discovery data to maximise the success of preclinical discovery projects.

Headquartered in Cambridge, UK, Optibrium also has offices in Boston and San Francisco, USA.

Optibrium's CEO Matt Segall said, "The space will enable us to accommodate new employees and provide the exciting opportunity to accelerate our growth plans. We look forward to welcoming new, highly talented software specialists and scientists dedicated to delivering our best-in-class in silico technologies and Artificial Intelligence platforms."

For further information on Optibrium, StarDrop or Cerella, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

ENDS

Notes to Editors:

Matt Segall, CEO, Optibrium

For a high-resolution image please contact Zyme Communications.

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.

Media Contact
Sarah Jeffery
Zyme Communications
Email: sarah.jeffery@zymecommunications.com
Phone: +44 (0)7771 730919

Optibrium
John Norman
Head of Marketing
E-mail: john@optibrium.com 

Phone: +44 (0)1223 815903

About Optibrium Ltd

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium's lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company's new Augmented Chemistry™ products and services deliver proven artificial intelligence technologies that continuously learn from all available data to supplement researchers experience and skills.

Optibrium was founded in 2009 and is headquartered in Cambridge, UK, with offices in Boston, MA, and San Francisco, CA. The company works closely with over 160 customers and collaborators worldwide, including leading global pharma, biotech, agrochemical and flavouring companies and not-for-profit and academic groups.

For further information, visit www.optibrium.com